Price: $86.86, Change: $+2.40, Percent Change: +2.84%
Related Articles
Research
Research Alert: CFRA Maintains Hold Opinion On Shares Of Cisco Systems Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $40 to $125, based on 26.5x our FY 27 (Jul.) EPS estimate, a premium to its one-year forward average P/E of 18.0x, reflecting recent strong results. We increase our FY 26 EPS estimate by $0.16 to $4.28 and FY 27's by $0.28 to $4.71. Networking product orders accelerated, with more than 50% growth, due to considerable gains in areas such as service provider routing, compute, data center switching, campus switching, wireless, enterprise routing, and industrial IoT products. The AI infrastructure business showed substantial order growth, particularly from hyperscalers, with YTD totals already exceeding previous expectations and a revised outlook for further increases. CSCO secured five new design wins with hyperscalers in the third quarter, including wins for both optics and systems, marking expansion in its AI infrastructure offerings.
$CSCO
Research
Superior Plus Target Raised To C$7.50 From $6, Keeps Sector Perform at National Bk With "Data Centre Demand Breathing New Life Into CNG Outlook"
Price: $7.80, Change: $+0.39, Percent Change: +5.26%
$SPB.TO
Research
Research Alert: CFRA Maintains Hold Rating On Shares Of Elevance Health
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $435 from $360, reflecting 16.2x our 2026 EPS estimate, above ELV's three- and five-year historical forward averages of 12.7x and 14.1x, respectively. We lift our 2026 EPS estimate by $0.14 to $26.91 and our 2027 EPS estimate by $0.14 to $29.22. We upgraded our 12-month fundamental outlook for the managed health care sub-industry to neutral from negative, with ELV and peers taking steps to improve profitability via increased medical premiums, strategic portfolio shifts/exits, and heightened focus on cost control within an elevated medical cost landscape. We anticipate that these actions may improve margins and profitability looking ahead to 2027-2028 and think valuations could gradually improve.
$ELV